Monopar Therapeutics Inc. (MNPR) Financial Ratios
11 years of historical data (2015–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
4.40
↓-42% vs avg
5yr avg: 7.60
30Y Low3.5·High69.6
ROE
↑
-14.2%
↓+76% vs avg
5yr avg: -59.6%
30Y Low-266%·High-14%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MNPR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Monopar Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $548M | $484M | $253M | $25M | $151M | $200M | $335M | $879M | — | — | — |
| Enterprise Value | $486M | $422M | $207M | $17M | $143M | $180M | $319M | $866M | — | — | — |
| P/E Ratio → | -44.20 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 4.40 | 3.51 | 4.59 | 4.41 | 14.94 | 10.57 | 21.37 | 69.59 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MNPR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
MNPR Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -14.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -14.2% | -14.2% | -51.4% | -107.2% | -72.4% | -52.6% | -44.5% | -43.2% | -39.0% | -265.9% | -42.5% |
| ROA | -13.6% | -13.6% | -46.1% | -81.7% | -62.3% | -48.7% | -41.7% | -40.9% | -37.4% | -258.1% | -41.4% |
| ROIC | -29.4% | -29.4% | -321.4% | -5671.9% | -2878.6% | — | — | — | -769.7% | -1784.1% | -118.7% |
| ROCE | -17.3% | -17.3% | -53.3% | -112.6% | -72.6% | -52.7% | -46.0% | -44.2% | -41.2% | -266.7% | -42.7% |
MNPR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $62M exceeds total debt of $154920, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | — | — | 0.00 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.45 | -0.83 | -1.30 | -0.81 | -1.07 | -1.07 | -1.05 | -1.00 | -0.93 | -0.73 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -32.27 | -343.07 | -163.83 |
Net cash position: cash ($62M) exceeds total debt ($154920)
MNPR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Monopar Therapeutics Inc.'s current ratio of 51.35x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.17x to 51.35x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 51.35 | 51.35 | 11.47 | 4.17 | 4.21 | 12.98 | 14.28 | 18.27 | 18.32 | 29.28 | 32.48 |
| Quick Ratio | 51.35 | 51.35 | 11.47 | 4.17 | 4.21 | 12.98 | 14.28 | 18.27 | 18.32 | 29.28 | 32.48 |
| Cash Ratio | 51.33 | 51.33 | 11.46 | 4.13 | 4.19 | 12.85 | 14.22 | 18.25 | 17.25 | 28.80 | 32.13 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
MNPR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Monopar Therapeutics Inc. returns 6.4% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 6.4% | 7.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 6.4% | 7.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $7M | $11M | $15M | $13M | $12M | $11M | $11M | $10M | $10M | $10M |
Peer Comparison
Compare MNPR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MNPRYou | $548M | -44.2 | — | — | — | — | -14.2% | -29.4% | — |
 CLDX | $2B | -8.5 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
 IMVT | $8B | -13.6 | — | — | — | — | -64.8% | — | — |
 TPVG | $192M | 3.9 | 8.5 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 NKTR | $1B | -6.9 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 ADXN | $5M | -0.8 | — | — | 100.0% | -9390.8% | -93.2% | -44.3% | — |
 CASI | $2M | -0.1 | — | — | 39.1% | -138.8% | -301.8% | -153.0% | — |
 AGEN | $128M | -902.9 | — | — | 29.6% | -18.0% | — | — | — |
 SNDX | $2B | -6.0 | — | — | 96.0% | -158.4% | -161.8% | -54.2% | — |
 KPTI | $82M | -0.5 | — | — | 95.9% | -62.1% | — | — | — |
 IQV | $29B | 21.8 | 12.6 | 14.2 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
| Healthcare Median | — | 22.0 | 14.1 | 18.7 | 63.6% | -4.8% | -32.4% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 11 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
MNPR — Frequently Asked Questions
Quick answers to the most common questions about buying MNPR stock.
What is Monopar Therapeutics Inc.'s P/E ratio?
Monopar Therapeutics Inc.'s current P/E ratio is -44.2x. This places it at the 50th percentile of its historical range.
What is Monopar Therapeutics Inc.'s ROE?
Monopar Therapeutics Inc.'s return on equity (ROE) is -14.2%. The historical average is -68.9%.
Is MNPR stock overvalued?
Based on historical data, Monopar Therapeutics Inc. is trading at a P/E of -44.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.